Uniphar | Development ads

The average oncology Phase 3 trial now costs more than $65M. That's a big bet to place on the wrong dose. Model-informed drug development helps leadership teams make those calls with stronger evidence, before significant time, capital and program value are at risk. Download our executive guide for a practical look at what MIDD delivers and when to bring it in.

Using MIDD isn't an advantage anymore. Using it early is. The sponsors who come out ahead bring modeling in early enough to shape their biggest development decisions. Our new executive guide shows where it changes outcomes, from dose selection to Phase 3 design, and how to build a dose package that holds up with regulators and investors.

Dose justification is one of the most underinvested decisions in drug development. There Is No Shortcut to Phase 3: An Executive MIDD Guide shows how to build a defensible dose-selection strategy before Phase 3 begins. What you'll get: ✅The Phase 2 shortcuts that quietly increase dose-selection risk ✅What ICH M15 expects for planning and documenting MIDD evidence ✅A 5-practice checklist to test whether your program is Phase 3-ready ✅A case study: how one sponsor avoided a repeat Phase 2 study Download the free guide to pressure-test your dose strategy before Phase 3.

The best time to address dose-selection risk is before Phase 3, not after regulators ask for more evidence. Get the executive guide to MIDD.

Is your Phase 2 dose strong enough to carry into Phase 3? Our new executive guide shows where dose selection goes wrong and how MIDD helps you defend it.

The best time to address dose-selection risk is before Phase 3, not after regulators ask for more evidence. With ICH M15 now in effect, FDA and EMA share a common framework for model-informed drug development. Our new executive guide explains where MIDD has the most influence, what regulators expect and the questions leaders should ask before End-of-Phase 2. Download a free copy of the guide now.